サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1265967

ショートリードシーケンスの世界市場

Short-Read Sequencing
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 88 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
ショートリードシーケンスの世界市場
出版日: 2023年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 88 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ショートリードシーケンスの世界市場は2030年に344億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に179億米ドルと推定されるショートリードシーケンスの世界市場は、2030年までに344億米ドルの改定規模に達し、2022年から2030年にかけてCAGR8.5%の成長を遂げると予測されます。本レポートで分析したセグメントの1つである次世代シーケンサーは、CAGR8%を記録し、分析期間終了時には224億米ドルに達すると予測されます。パンデミック後の回復を考慮し、サンガーシーケンスセグメントの成長は、今後8年間のCAGRが9.4%に修正される見込みです。

米国市場は53億米ドル、中国はCAGR7.6%の成長予測

米国のショートリードシーケンス市場は、2022年に53億米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが7.6％となり、2030年には58億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ7.5％と6.3％の成長が予測されています。欧州では、ドイツがCAGR約6.2%で成長すると予測されています。

調査対象企業の例

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Fasteris
  • General Electric
  • Genewiz
  • GenScript
  • Illumina, Inc
  • Macrogen, Inc
  • Qiagen
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP22761

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Short-Read Sequencing Market to Reach $34.4 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Short-Read Sequencing estimated at US$17.9 Billion in the year 2022, is projected to reach a revised size of US$34.4 Billion by 2030, growing at aCAGR of 8.5% over the period 2022-2030. Next-Generation Sequencing, one of the segments analyzed in the report, is projected to record 8% CAGR and reach US$22.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Sanger Sequencing segment is readjusted to a revised 9.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $5.3 Billion, While China is Forecast to Grow at 7.6% CAGR

The Short-Read Sequencing market in the U.S. is estimated at US$5.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.5% and 6.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Select Competitors (Total 32 Featured) -

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Fasteris
  • General Electric
  • Genewiz
  • GenScript
  • Illumina, Inc
  • Macrogen, Inc
  • Qiagen
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Short-Read Sequencing - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Next-Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 16: World 8-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World 8-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World 8-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 22: World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 23: World Short-Read Sequencing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 25: USA 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 29: USA 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Canada 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Canada 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • JAPAN
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Japan 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Japan 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • CHINA
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 43: China 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 47: China 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • EUROPE
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 49: Europe 8-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 53: Europe 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Europe 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • FRANCE
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 59: France 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 61: France 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • GERMANY
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Germany 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Germany 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 71: Italy 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 73: Italy 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • UNITED KINGDOM
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 77: UK 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 79: UK 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of World 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 95: Rest of World 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 97: Rest of World 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030

IV. COMPETITION